ProMIS Neurosciences Inc PMN

Healthcare Biotechnology

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.

NDAQ:PMN - Post by User

ProMIS Neurosciences Inc > Listing requirements for Nasdaq

<< Previous

Bullboard Posts

Next >>

Comment by Mole101on Oct 07, 2021 2:51pm

169 Views

Post# 33983381

RE:RE:RE:RE:Listing requirements for Nasdaq

Long term good news, short term the SP needs to pick up to be able to make it there, as of now they would need at 25/1 split to get close to that 4$ requirement. I think they are just trying to justify the reverse split and make it more attractive to future investors 500 million shares it’s a big hill ..